Assignee
SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD
CN·0 granted patents·9 pending applications·0 citations·filing 2021–2023
Top patents by PatentIndex Score
9 records- 0165US2025368667A1Usp1 inhibitorSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2023·Application pending·0 cites
- 0260US2025206763A1Enpp1 inhibitorSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2023·Application pending·0 cites
- 0358US2024141038A1Antibody against nkp46 and application thereofSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2022·Application pending·0 cites
- 0455US2024239878A1Binding molecule against dll3 and use thereofSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2022·Application pending·0 cites
- 0553US2024010748A1Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibodySHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2021·Application pending·0 cites
- 0650US2025136680A1Bispecific antigen-binding molecule and use thereofSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2023·Application pending·0 cites
- 0750US2024351997A1Novel parp7 inhibitor and use thereofSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2022·Application pending·0 cites
- 0849US2025009745A1Cdk inhibitorSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2022·Application pending·0 cites
- 0949US2025042889A13clpro protease inhibitorSHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI QILU PHARMACEUTICAL RES AND DEVELOPMENT CENTRE LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →